Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06265233 · ClinicalTrials.gov registry record · NA
ERP Plus Improv Group Therapy for OCD (IMPROVE Study)
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT06265233: Completed NA study, sponsored by Stanford University.
NCT06265233 is a NA study that has completed, run by Stanford University. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06265233, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this study is to pilot test a novel group therapy intervention for adults with OCD.
Primary Outcome
Change in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% change on the YBOCS.
Interventions
- OTHER Group Improv sessions
- BEHAVIORAL Group Exposure and Response Prevention (ERP) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2025-04-18 |
| Phase | NA |
What the finished NCT06265233 record still lists
NCT06265233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Group Improv sessions is the first listed.
NCT06265233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06265233 about?
NCT06265233 is a clinical study titled "ERP Plus Improv Group Therapy for OCD (IMPROVE Study)". The goal of this study is to pilot test a novel group therapy intervention for adults with OCD.
What is the current status of trial NCT06265233?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2024-11-19. Estimated completion is 2025-04-18.
What interventions are being tested in trial NCT06265233?
The interventions under investigation include: Group Improv sessions (OTHER), Group Exposure and Response Prevention (ERP) Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06265233?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06265233's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI